Gastrointestinal Cancer
Conditions
Keywords
Gastrointestinal Tumors, DB-1324
Brief summary
This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.
Detailed description
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2 study to explore the safety, tolerability, and efficacy of DB-1324 in participants with malignant GI tumors. The Phase 1, which includes Dose Escalation, Backfill, and Dose Expansion to identify the MTD and determine the RDEs and RP2D. Phase 2 will confirm the safety, tolerability, and explore efficacy in selected malignant GI tumors. For both Phase 1 and Phase 2, participants will receive study treatment until 1) disease progression, 2) loss of clinical benefit in the opinion of the investigator, 3) unacceptable toxicity, 4) withdrawal from study treatment by participant, 5) lost to follow up, or 6) another criterion for discontinuation is met, whichever occurs first.
Interventions
DRUGDB-1324
Administered I.V.
Sponsors
DualityBio Inc.
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Pathologically documented advanced/unresectable, or metastatic GI tumor. 2. Have relapsed or progressed on or after standard systemic treatments, or are intolerant to standard treatment, or for which no standard treatment is available. 3. At least one measurable lesion as assessed by the investigator according to response evaluation criteria in RECIST v1.1. 4. Has a life expectancy of ≥ 3 months. 5. Has an ECOG PS of 0-1. 6. Has LVEF ≥ 50% by either ECHO or MUGA within 28 days before enrollment. 7. Has adequate organ functions within 7 days prior to Day 1 of Cycle 1. 8. Has an adequate treatment washout period before Day 1 of Cycle 1. 9. Participants are willing to provide archived tumor tissue or undergo a tumor biopsy for the measurement of CDH17 levels and other biomarkers. 10. Other protocol-defined Inclusion criteria apply.
Exclusion criteria
1. Prior treatment with CDH17 targeted therapy. 2. Prior treatment with ADC with topoisomerase I inhibitor. 3. Has chronic enteritis or inflammatory bowel disease. Or has clinically significant bleeding of GI tract or adjacent organs within 1 month prior to the first dose of study treatment. Or has clinically significant obstruction and/or perforation and/or fistulae (including prior GI fistula operation) of GI tract or adjacent tissues within 6 months prior to the first dose of study treatment. 4. Uncontrolled or significant cardiovascular disease. 5. Has a medical history of cerebrovascular accident including transient ischemic attack within 6 months before enrollment. 6. Has a history of (non-infectious) ILD/pneumonitis that required steroids, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. 7. Have a lung-specific intercurrent clinically significant illness. 8. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals. 9. Has clinically active brain metastases. 10. Has unresolved toxicities from previous anticancer therapy. 11. Other protocol-defined
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation and Backfill parts: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0. | Up to safety follow-up visit, approximately 30 days post-treatment | Percentage of participants in dose escalation and backfill parts with DLTs |
| Dose Escalation and Backfill parts: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0. | Up to safety follow-up visit, approximately 30 days post-treatment | Percentage of participants with SAEs in dose escalation and backfill parts graded according to NCI CTCAE v5.0 |
| Dose Escalation and Backfill parts: Percentage of participants with Treatment Emergent Adverse Events (TEAEs) , Grade ≥ 3 TEAE, TEAE leading to dose reduction/interruption/discontinuation | Up to safety follow-up visit, approximately 30 days post-treatment | Percentage of participants who experienced any of the above TEAEs in dose escalation and backfill parts graded according to NCI CTCAE v5.0 |
| Dose Escalation and Backfill parts: Maximum Tolerated Dose(MTD) of DB-1324 | Up to safety follow-up visit, approximately 30 days post-treatment | MTD will be determined by evaluating the incidence of DLTs during the DLT assessment period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation and Backfill parts: Recommended Dose for Expansions(RDEs) | Up to the completion of Phase 1, assessed up to 12 months | RDEs will be based on the data collected during dose escalation and backfill parts |
| Dose Escalation, Backfill and Expansion parts: Recommended Phase 2 Dose(RP2D) | From the beginning of first patient in (FPI) to the end of study, approximately 36 months | RP2D will be based on the data collected during dose escalation, backfill and expansion parts |
| Dose Escalation and Backfill parts: Objective Response Rate (ORR) | From the beginning of first patient in (FPI) to the end of study, approximately 36 months | ORR will be determined by investigator per RECIST v1.1, defined as the percentage of participants who had a best response rating of CR and PR |
| Dose Escalation and Backfill parts: Duration of Response (DoR) | From the beginning of first patient in (FPI) to the end of study, approximately 36 months | DoR will be determined by investigator per RECIST v1.1, defined as the time from earliest date of documented CR or PR to the date of documented disease progression or death (by any cause, in the absence of progression) |
| Dose Escalation and Backfill parts: Disease Control Rate (DCR) | From the beginning of first patient in (FPI) to the end of study, approximately 36 months | DCR will be determined by investigator per RECIST v1.1, defined as the proportion of participants with best overall response of CR, PR, or SD with confirmation over a period of at least 6 weeks. |
| Dose Escalation and Backfill parts: Time to Response (TTR) | From the beginning of first patient in (FPI) to the end of study, approximately 36 months | TTR will be determined by investigator per RECIST v1.1, defined as the time from the first administration to first documented CR or PR. |
| Dose Escalation and Backfill parts: Progression Free Survival (PFS) | From the beginning of first patient in (FPI) to the end of study, approximately 36 months | PFS will be determined by investigator per RECIST v1.1, defined as the time from the first administration to documented disease progression or death (by any cause, in the absence of progression), whichever occurs first. |
| Dose Escalation and Backfill parts: Pharmacokinetic-AUClast | Up to safety follow up visit, approx. 30 days post-treatment | Area under the concentration-time curve from time 0 to the last of DB-1324, total anti-CDH17 antibody, and unconjugated payload. |
| Dose Escalation and Backfill parts: Pharmacokinetic-AUC0-τ | Up to safety follow up visit, approx. 30 days post-treatment | Area under the concentration-time curve from time 0 to time tau of DB-1324, total anti-CDH17 antibody, and unconjugated payload. |
| Dose Escalation and Backfill parts: Pharmacokinetic-Cmax | Up to safety follow up visit, approx. 30 days post-treatment | Maximum observed plasma concentration (Cmax) of DB-1324, total anti-CDH17 antibody, and unconjugated payload. |
| Dose Escalation and Backfill parts: Pharmacokinetic-Tmax | Up to safety follow up visit, approx. 30 days post-treatment | Time to Cmax of DB-1324, total anti-CDH17 antibody, and unconjugated payload. |
| Dose Escalation and Backfill parts: Pharmacokinetic-Cthroug | Up to safety follow up visit, approx. 30 days post-treatment | Trough concentration |
| Dose Escalation and Backfill parts: Anti-drug antibody (ADA) prevalence | Up to safety follow up visit, approx. 30 days post-treatment | Percentage of participants who are ADA positive at any point |
Countries
Australia, China, United States
Contacts
CONTACTZhaochuan Wang
CONTACTYuanyuan Sun
STUDY_DIRECTORLily Hu
DualityBio Inc.
Outcome results
None listed